WO2023118820 - CANCER SPECIFIC T-CELL RECEPTORS
National phase entry is expected:
Publication Number
WO/2023/118820
Publication Date
29.06.2023
International Application No.
PCT/GB2022/053273
International Filing Date
16.12.2022
Title **
[English]
CANCER SPECIFIC T-CELL RECEPTORS
[French]
RÉCEPTEURS DE LYMPHOCYTES T SPÉCIFIQUES DU CANCER
Applicants **
CONTINUUM LIFE SCIENCES LIMITED
2nd Floor, Berkeley Square House
Berkeley Square
London W1J 6BD, GB
Inventors
SEWELL, Andrew
Cardiff University School of Medicine
Henry Wellcome Building, Heath Park
Cardiff CF14 4XN, GB
RIUS, Cristina
Cardiff University School of Medicine
Henry Wellcome Building, Heath Park
Cardiff CF14 4XN, GB
DOLTON, Gary
Cardiff University School of Medicine
Henry Wellcome Building, Heath Park
Cardiff CF14 4XN, GB
WOOLLEY, Rachel
Monarch House, 7 Barton Lane
Abingdon Science Park
Abingdon OX14 3NB, GB
Priority Data
2118699.4
21.12.2021
GB
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| * | |
International Searching Authority |
EPO
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Translation |
|
Recalculate
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing | 1295 | |
| EPO | Filing, Examination | 6194 | |
| Japan | Filing | 593 | |
| South Korea | Filing | 575 | |
| USA | Filing, Examination | 3910 |
Total: 12567 USD
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Abstract[English]
The present invention provides novel T cell receptor (TCR) based molecules which are selective for IMP2. The TCR of the invention are of use for the diagnosis, treatment and prevention of IMP2 expressing cancerous diseases. Further provided are nucleic acids encoding the TCR of the invention, vectors comprising these nucleic acids, recombinant cells expressing the TCR and pharmaceutical compositions comprising the compounds of the invention.[French]
La présente invention concerne de nouvelles molécules à base de récepteurs de lymphocytes T (TCR) qui sont sélectives pour IMP2. Le TCR de l'invention est utile pour le diagnostic, le traitement et la prévention de maladies cancéreuses exprimant IMP2. L'invention concerne en outre des acides nucléiques codant pour le TCR de l'invention, des vecteurs comprenant ces acides nucléiques, des cellules recombinantes exprimant le TCR et des compositions pharmaceutiques comprenant les composés de l'invention.